Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 13/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581807 | 0.86 | PLG (0.43) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL598801 | 0.83 | PLG (0.41) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581721 | 0.83 | PLG (0.41) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL3073977 | 0.83 | PLG (0.41) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581306 | 0.79 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581704 | 0.79 | PLG (0.56) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581283 | 0.76 | PLG (0.57) | PLGGABRA1GABRG2GABRB3SIGMAR1 | |
| Acetic Acid SCHEMBL27853124 | 0.75 | PLG (0.51) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL581069 | 0.74 | PLG (0.54) | PLGGABRA1GABRG2GABRB3SIGMAR1 | |
| SCHEMBL581237 | 0.74 | PLG (0.51) | PLGGABRA1GABRG2GABRB3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |